AHF Labels Gilead ‘War Profiteer’ and ‘Greedy Bastards!’ after Company Sets COVID Drug Price at $2K to $3K

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

AIDS Healthcare Foundation (AHF) today harshly criticized Gilead Sciences over its pricing of remdesivir, the newly approved COVID-19 treatment. Gilead, which developed the drug years earlier (with as much $70 million in government research and development funding) as a possible Ebola treatment, announced earlier today that it has set the price for remdesivir between $2,300 and $3,100 per patient for a five day course of treatment.

According to Zachary Brennan reporting in PoliticoPro (6/29/20), Gilead ¦set the price for its coronavirus treatment remdesvir at $390 per vial for the U.S. government and developed countries. That puts the price of a five-day treatment course at $2,340 per patient for people enrolled in federal health programs like Medicare and Medicaid but private insurers will pay $520 per vial, or $3,120 for five days of treatment, the company said Monday. The U.S. is the only country for which Gilead has set tiered pricing.

Gilead Sciences unmasked itself today as both a war profiteer and greedy bastardsa depressing feat and spectacularly tone-deaf response to a global pandemic that has so far killed over half-a-million people worldwide, including more than 120,000 deaths in the U.S., said AHF President Michael Weinstein. U.S. taxpayers paid for much of the research for this drug. Now, Medicaid and Medicare are going to pay a premium for the prescriptions for this drug for patients in the United States and patients covered by private insurers will pay even more. Its unconscionable.

In early May, AHF issued a statement demanding that Gilead price remdesivir at no more than one U.S. dollar per dose. AHF further demanded that Gilead Sciences also disclose all its public research and development costs and all public investments in connection with the development of remdesivir.

AHFs dollar per dose demand is based on a University of Liverpool research study, Minimum costs to manufacture new treatments for COVID-19 that allows for recovery of the cost of manufacturing plus a reasonable profit.

Gileads move todayand the likely acquiescence by both government and private insurers without a real challenge or fightset a terrible, terrible precedent, added Weinstein. This out-of-whack pricing by Gilead now pits this disease against all others for governments trying as best they can to cope with the economic, social and medical havoc wreaked by COVID-19as well as against governments trying to feed and shelter their people during this crisis. This also sets the baseline for pricing of any and all future COVID-19 treatments, something we saw with AIDS and the pricing of its first drug, AZTdrug pricing repercussions we still live, and die with, today.

About AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.4 million people in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare.

WASHINGTON

John Hassell, National Director of Advocacy, AHF

+1.202.774.4854 [cell] [email protected]

LOS ANGELES

Ged Kenslea, Senior Director, Communications, AHF

+1.323.791.5526 [cell] +.323.308.1833 [work] [email protected]